Influence of beta-blocker therapy on aortic blood flow in patients with bicuspid aortic valve

Int J Cardiovasc Imaging. 2016 Apr;32(4):621-8. doi: 10.1007/s10554-015-0819-3. Epub 2016 Jan 27.

Abstract

In patients with bicuspid aortic valve (BAV), beta-blockers (BB) are assumed to slow ascending aorta (AAo) dilation by reducing wall shear stress (WSS) on the aneurysmal segment. The aim of this study was to assess differences in AAo peak velocity and WSS in BAV patients with and without BB therapy. BAV patients receiving BB (BB+, n = 30, age: 47 ± 11 years) or not on BB (BB-, n = 30, age: 46 ± 13 years) and healthy controls (n = 15, age: 43 ± 11 years) underwent 4D flow MRI for the assessment of in vivo aortic 3D blood flow. Peak systolic velocities and 3D WSS were calculated at the anterior and posterior walls of the AAo. Both patient groups had higher maximum and mean WSS relative to the control group (p = 0.001 to p = 0.04). WSS was not reduced in the BB+ group compared to BB- patients in the anterior AAo (maximum: 1.49 ± 0.47 vs. 1.38 ± 0.49 N/m(2), p = 0.99, mean: 0.76 ± 0.2 vs. 0.74 ± 0.18 N/m(2), p = 1.00) or posterior AAo (maximum: 1.45 ± 0.42 vs. 1.39 ± 0.58 N/m(2), p = 1.00; mean: 0.65 ± 0.16 vs. 0.63 ± 0.16 N/m(2), p = 1.00). AAo peak velocity was elevated in patients compared to controls (p < 0.01) but similar for BB+ and BB- groups (p = 0.42). Linear models identified significant relationships between aortic stenosis severity and increased maximum WSS (β = 0.186, p = 0.007) and between diameter at the sinus of Valsalva and reduced mean WSS (β = -0.151, p = 0.045). Peak velocity and systolic WSS were similar for BAV patients irrespective of BB therapy. Further prospective studies are needed to investigate the impact of dosage and duration of BB therapy on aortic hemodynamics and development of aortopathy.

Keywords: 4D flow MRI; Aortic dilatation; Beta blocker; Bicuspid aortic valve.

Publication types

  • Research Support, N.I.H., Extramural

MeSH terms

  • Adrenergic beta-Antagonists / therapeutic use*
  • Adult
  • Aorta, Thoracic / diagnostic imaging
  • Aorta, Thoracic / drug effects*
  • Aorta, Thoracic / physiopathology
  • Aortic Aneurysm, Thoracic / diagnostic imaging
  • Aortic Aneurysm, Thoracic / drug therapy*
  • Aortic Aneurysm, Thoracic / etiology
  • Aortic Aneurysm, Thoracic / physiopathology
  • Aortic Valve / abnormalities*
  • Aortic Valve / diagnostic imaging
  • Aortic Valve / physiopathology
  • Aortic Valve Stenosis / diagnostic imaging
  • Aortic Valve Stenosis / etiology*
  • Aortic Valve Stenosis / physiopathology
  • Bicuspid Aortic Valve Disease
  • Blood Flow Velocity
  • Cross-Sectional Studies
  • Disease Progression
  • Female
  • Heart Valve Diseases / complications
  • Heart Valve Diseases / diagnostic imaging
  • Heart Valve Diseases / drug therapy*
  • Heart Valve Diseases / physiopathology
  • Hemodynamics / drug effects*
  • Humans
  • Magnetic Resonance Imaging
  • Male
  • Middle Aged
  • Perfusion Imaging / methods
  • Predictive Value of Tests
  • Regional Blood Flow
  • Retrospective Studies
  • Risk Factors
  • Treatment Outcome

Substances

  • Adrenergic beta-Antagonists